Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 02:25PM ET
5.41
Dollar change
-0.33
Percentage change
-5.84
%
IndexRUT P/E- EPS (ttm)-4.56 Insider Own1.41% Shs Outstand75.37M Perf Week-9.77%
Market Cap411.32M Forward P/E- EPS next Y-1.87 Insider Trans-5.26% Shs Float75.03M Perf Month-29.71%
Income-337.40M PEG- EPS next Q-0.94 Inst Own113.82% Short Float14.13% Perf Quarter-40.34%
Sales198.84M P/S2.07 EPS this Y-96.83% Inst Trans0.10% Short Ratio9.05 Perf Half Y-23.12%
Book/sh2.66 P/B2.03 EPS next Y36.67% ROA-47.87% Short Interest10.60M Perf Year-74.38%
Cash/sh7.45 P/C0.73 EPS next 5Y- ROE-287.12% 52W Range5.25 - 22.75 Perf YTD-39.88%
Dividend Est.- P/FCF- EPS past 5Y-12.34% ROI-56.17% 52W High-76.24% Beta0.68
Dividend TTM- Quick Ratio3.41 Sales past 5Y3.07% Gross Margin69.95% 52W Low2.95% ATR (14)0.38
Dividend Ex-Date- Current Ratio3.47 EPS Y/Y TTM-4.33% Oper. Margin-171.72% RSI (14)23.18 Volatility5.08% 5.80%
Employees380 Debt/Eq2.02 Sales Y/Y TTM-6.21% Profit Margin-169.68% Recom1.69 Target Price14.87
Option/ShortYes / Yes LT Debt/Eq1.99 EPS Q/Q-15.12% Payout- Rel Volume0.43 Prev Close5.74
Sales Surprise8.08% EPS Surprise-1.94% Sales Q/Q-19.35% EarningsFeb 15 AMC Avg Volume1.17M Price5.41
SMA20-18.96% SMA50-27.77% SMA200-43.44% Trades Volume391,067 Change-5.84%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Downgrade Guggenheim Buy → Neutral
Dec-05-23Upgrade Citigroup Neutral → Buy $7 → $10
Nov-20-23Initiated Citigroup Neutral $7
Sep-22-23Downgrade Wells Fargo Overweight → Equal Weight $24 → $8
Sep-21-23Downgrade William Blair Outperform → Mkt Perform
Sep-06-23Resumed Evercore ISI Outperform $30
Jul-21-23Initiated JP Morgan Overweight $26
Jun-07-23Resumed Piper Sandler Neutral $22
May-22-23Initiated TD Cowen Outperform $30
May-05-23Upgrade Bryan Garnier Sell → Neutral
Today 07:05AM
03:00AM
Apr-04-24 04:30PM
Apr-03-24 04:30PM
Mar-13-24 05:00PM
07:05AM Loading…
Mar-11-24 07:05AM
Feb-26-24 04:30PM
Feb-23-24 07:05AM
02:00AM
Feb-16-24 09:52AM
Feb-15-24 04:01PM
Feb-08-24 04:30PM
Feb-01-24 04:30PM
Jan-25-24 04:05PM
Jan-08-24 07:00AM
04:30PM Loading…
Jan-02-24 04:30PM
Dec-14-23 07:30AM
Dec-04-23 04:05PM
Nov-21-23 04:30PM
Nov-09-23 06:26PM
Nov-07-23 04:01PM
Nov-03-23 10:46AM
Oct-24-23 04:30PM
Oct-13-23 04:30PM
Oct-11-23 05:00PM
Sep-26-23 04:30PM
Sep-22-23 09:38AM
Sep-21-23 07:30AM
Sep-11-23 05:00PM
Sep-05-23 08:30AM
08:30AM Loading…
08:30AM
Aug-31-23 04:30PM
Aug-24-23 04:30PM
Aug-14-23 05:00PM
Aug-08-23 06:03AM
Aug-03-23 04:01PM
Jul-26-23 12:28PM
Jul-20-23 04:30PM
Jul-17-23 08:00AM
08:00AM
Jul-11-23 05:00PM
Jun-14-23 05:00PM
Jun-08-23 04:30PM
Jun-01-23 04:30PM
May-31-23 07:00AM
May-11-23 05:00PM
May-04-23 04:01PM
May-01-23 04:05PM
Apr-26-23 04:30PM
Apr-13-23 05:00PM
Apr-01-23 04:30AM
Mar-28-23 04:30PM
Mar-23-23 04:30PM
Mar-14-23 05:00PM
04:30PM
Mar-03-23 04:05PM
Feb-28-23 10:36PM
Feb-27-23 04:01PM
Feb-25-23 07:35AM
Feb-23-23 04:01PM
Feb-17-23 06:30PM
04:04PM
04:04PM
Feb-16-23 04:30PM
Feb-13-23 05:00PM
Feb-08-23 04:30PM
Jan-12-23 07:00PM
Jan-09-23 07:00AM
Jan-03-23 04:30PM
Dec-14-22 05:00PM
Nov-16-22 05:00PM
Nov-15-22 08:00AM
Nov-09-22 04:30PM
Oct-27-22 04:01PM
Oct-26-22 04:30PM
Oct-20-22 04:30PM
Oct-13-22 04:05PM
Oct-11-22 05:00PM
Sep-14-22 05:00PM
Aug-25-22 04:30PM
Aug-22-22 07:00AM
Aug-11-22 05:00PM
Aug-04-22 07:00AM
Aug-03-22 04:05PM
Jul-28-22 04:30PM
Jul-12-22 05:00PM
Jun-20-22 09:18AM
Jun-14-22 05:00PM
Jun-02-22 04:30PM
May-17-22 04:30PM
May-16-22 04:09PM
07:00AM
May-11-22 05:00PM
May-05-22 04:01PM
May-03-22 04:30PM
Apr-28-22 04:30PM
Apr-20-22 04:30PM
Apr-12-22 05:00PM
Apr-11-22 08:08AM
Apr-06-22 04:30PM
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cline Christopher R.CHIEF FINANCIAL OFFICERApr 11 '24Sale6.745436470,849Apr 12 04:05 PM
Dube Eric MCHIEF EXECUTIVE OFFICERFeb 01 '24Sale8.7019,122166,435350,600Feb 02 04:06 PM
REED ELIZABETH ESVP, GC & CORPORATE SECRETARYFeb 01 '24Sale8.714,76441,49576,270Feb 02 04:05 PM
ROTE WILLIAM E.SENIOR VICE PRESIDENT, R&DFeb 01 '24Sale8.714,76441,49580,720Feb 02 04:05 PM
Heerma PeterCHIEF COMMERCIAL OFFICERFeb 01 '24Sale8.534,19535,78999,503Feb 02 04:05 PM
Cline Christopher R.CHIEF FINANCIAL OFFICERFeb 01 '24Sale8.533,81832,57370,903Feb 02 04:05 PM
Calvin SandraSVP, CHIEF ACCOUNTING OFFICERFeb 01 '24Sale8.532,82024,05852,017Feb 02 04:05 PM
Inrig JulaCHIEF MEDICAL OFFICERFeb 01 '24Sale8.532,17418,54758,074Feb 02 04:05 PM
Dube Eric MCHIEF EXECUTIVE OFFICERJan 23 '24Sale8.967,87370,542234,722Jan 25 04:10 PM
ROTE WILLIAM E.SENIOR VICE PRESIDENT, R&DJan 23 '24Sale8.962,06218,47660,484Jan 25 04:10 PM
REED ELIZABETH ESVP, GC & CORPORATE SECRETARYJan 23 '24Sale8.962,06218,47656,034Jan 25 04:10 PM
Heerma PeterCHIEF COMMERCIAL OFFICERJan 23 '24Sale9.071,55914,13878,698Jan 25 04:10 PM
Calvin SandraSVP, CHIEF ACCOUNTING OFFICERJan 23 '24Sale9.079108,25241,337Jan 25 04:10 PM
Cline Christopher R.CHIEF FINANCIAL OFFICERJan 23 '24Sale9.078537,73549,721Jan 25 04:10 PM
Inrig JulaChief Medical OfficerJan 04 '24Sale9.174404,03535,248Jan 05 04:11 PM
Inrig JulaChief Medical OfficerJan 03 '24Sale9.482,06919,61335,688Jan 05 04:11 PM
Heerma PeterChief Commercial OfficerOct 03 '23Sale8.253,09125,50480,257Oct 04 04:05 PM
Dube Eric MChief Executive OfficerSep 05 '23Sale14.714,45565,533242,595Sep 05 08:10 PM
ROTE WILLIAM E.Senior Vice President, R&DSep 05 '23Sale14.711,81526,69961,173Sep 05 08:13 PM
REED ELIZABETH ESVP, GC & Corporate SecretarySep 05 '23Sale14.711,81526,69958,096Sep 05 08:12 PM
Cline Christopher R.Chief Financial OfficerSep 05 '23Sale14.714576,72350,574Sep 05 08:15 PM
Calvin SandraSVP, Chief Accounting OfficerMay 11 '23Sale16.121221,96742,247May 12 04:06 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 10 '23Sale16.5982513,68756,611May 12 04:11 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 10 '23Sale16.5982513,68759,211May 12 04:09 PM
Cline Christopher R.Chief Financial OfficerMay 10 '23Sale16.594557,54851,031May 12 04:14 PM
Calvin SandraSVP, Chief Accounting OfficerMay 10 '23Sale16.594367,23342,369May 12 04:06 PM